August 28, 2016 4:14 PM ET

Biotechnology

Company Overview of Regulus Therapeutics Inc.

Executive Profile

Paul C. Grint M.D.

Chief Executive Officer, President and Director, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 11 different industries.

See Board Relationships
58$5,006,729
As of Fiscal Year 2015

Background

Dr. Paul C. Grint, M.D., has been the Chief Executive Officer and President of Regulus Therapeutics Inc. since June 1, 2015 and served as its Chief Medical Officer from June 16, 2014 to June 1, 2015. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to Regulus, Dr. Grint served as the President at Cerexa, Inc. and was responsible ...

Corporate Headquarters

3545 John Hopkins Court
San Diego, California 92121

United States

Phone: 858-202-6300
Fax: --

Board Members Memberships

2008-Present
Director
2015-Present
Non-Executive Director and Member of Compensation Committee
2015-Present
Chief Executive Officer, President and Director
2016-Present
Director

Education

Bachelor's Degree
Barts & The London School of Medicine & Dentistry, Queen Mary University of London
MD
Saint Bartholomew Medical School, London University

Other Affiliations

Annual Compensation

Salary$446,532
Total Annual Compensation$446,532

Stocks Options

All Other Compensation$4,022
Exercisable Options$140,416
Unexercisable Options$730,454
Total Number of Options$973,522

Total Compensation

Total Annual Cash Compensation$700,554
Total Short Term Compensation$446,532
Other Long Term Compensation$4,022
Total Calculated Compensation$5,006,729
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Andrew Rackear J.D.Chief Executive Officer and Secretary
Enzon Pharmaceuticals Inc.
$358.0K
Joseph W. Ramelli Chairman, Interim Chief Executive Officer, Interim President, Chairman of Nominating & Corporate Governance Committee, Member of Audit Committee and Member of Compensation Committee
Marina Biotech, Inc.
--
Gregory West CAChief Executive Officer
Benitec Biopharma Limited
$230.0K
Douglas M. Fambrough III, Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dicerna Pharmaceuticals, Inc.
$490.0K
Robert W. Overell Ph.D.Co-Founder, Chief Executive Officer, President and Director
PhaseRx, Inc.
$324.2K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Regulus Therapeutics Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.